Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)


21 Oct 2023


Poster session 18


Tumour Immunology;  Immunotherapy

Tumour Site

Hepatobiliary Cancers


Hongjae Chon


Annals of Oncology (2023) 34 (suppl_2): S594-S618. 10.1016/S0923-7534(23)01939-7


H. Chon1, Y.S. Song2, H. Yang3, I. Kim4, K. Hye-young5, W.S. LEE6, Y.B. Sang7, C. Kim8

Author affiliations

  • 1 Medical Oncology, Bundang Cha Medical Center, 13496 - Seongnam/KR
  • 2 Division Of Endocrinology And Metabolsim, CHA Bundang Medical Center, 13496 - Seongnam/KR
  • 3 Oncology, Bundang Cha Medical Center, 13496 - Seongnam/KR
  • 4 Medical Oncology, Inje University Haeundae Paik Hospital, 612-896 - Busan/KR
  • 5 Medical Oncology, Ulsan University Hospital, 44033 - Ulsan/KR
  • 6 Laboratory Of Translational Immuno-oncology, Bundang Cha Medical Center, 13496 - Seongnam/KR
  • 7 Hematology And Oncology, CHA Bundang Medical Center, 13496 - Seongnam/KR
  • 8 Medical Oncology Dept, Bundang Cha Medical Center, 13496 - Seongnam/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 993P


The combination of atezolizumab and bevacizumab (Ate/Bev) has become the new standard of care as first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies have reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological significance of thyroid dysfunction in patients with Ate/Bev has not been comprehensively addressed. In this study, we aim to comprehensively evaluate the clinical and immunological implications of thyroid dysfunction in unresectable HCC patients treated with Ate/Bev.


This study enrolled 208 patients with unresectable HCC treated with Ate/Bev from three Korean cancer centers. Thyroid adverse events (AEs) were reviewed, and cytokines and T cells in the blood samples were analyzed at baseline. For external validation, we analyzed clinical outcomes according to thyroid AEs in patients treated with Ate/Bev in the IMbrave150 study.


Forty-one (19.7%) out of 208 patients experienced thyroid dysfunction (hypothyroidism [17.3%] and thyrotoxicosis [5.8%]) after Ate/Bev treatment. The median time to onset of hypothyroidism and thyrotoxicosis after Ate/Bev treatment were 3.5 months and 1.3 months, respectively. Patients with thyroid AEs demonstrated significantly better results in terms of progression-free survival, overall survival, and objective response rate than those without thyroid AEs. These findings were still consistent even after adjusting for confounding factors. Furthermore, favorable survival outcomes in patients with thyroid AE were also validated in a cohort of IMbrave150 patients. While patients with thyrotoxicosis showed significantly lower level of baseline IL-6, patients with hypothyroidism did not show significant differences in circulating cytokine levels and CD8+ T cell fractions.


A fraction of patients with HCC treated with Ate/Bev experienced thyroid dysfunction, and the development of thyroid AEs was associated with favorable clinical outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

This publication is based on research using data from data contributors Roche that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication.


This work was supported by the National Research Foundation of Korea [NRF] grants funded by the Korean government [MSIT] [NRF-2023R1A2C2004339 to HJC, NRF-2023R1A2C2006375 to CK].


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.